Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Venous Thromboembolism-Pipeline Review, H1 2015

Venous Thromboembolism-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Venous Thromboembolism-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Venous Thromboembolism-Pipeline Review, H1 2015', provides an overview of the Venous Thromboembolism's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Venous Thromboembolism

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Venous Thromboembolism and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Venous Thromboembolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Venous Thromboembolism pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Venous Thromboembolism

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Venous Thromboembolism pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Venous Thromboembolism Overview 7

Therapeutics Development 8

Pipeline Products for Venous Thromboembolism-Overview 8

Pipeline Products for Venous Thromboembolism-Comparative Analysis 9

Venous Thromboembolism-Therapeutics under Development by Companies 10

Venous Thromboembolism-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Venous Thromboembolism-Products under Development by Companies 14

Venous Thromboembolism-Companies Involved in Therapeutics Development 15

Bayer AG 15

Daiichi Sankyo Company, Limited 16

Gamma Therapeutics, Inc. 17

GlycoMimetics, Inc. 18

Green Cross Corporation 19

Isis Pharmaceuticals, Inc. 20

Portola Pharmaceuticals, Inc. 21

Regado Biosciences, Inc. 22

Sanofi 23

Venous Thromboembolism-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

betrixaban-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

edoxaban tosylate-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Gammarin-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

GCC-2107-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

GMI-1271-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

ISIS-FXIRx-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Lysimab-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

REG-2-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

rivaroxaban-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

semuloparin-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Venous Thromboembolism-Recent Pipeline Updates 50

Venous Thromboembolism-Dormant Projects 69

Venous Thromboembolism-Discontinued Products 70

Venous Thromboembolism-Product Development Milestones 71

Featured News & Press Releases 71

Apr 15, 2015: Daiichi Sankyo's Once-Daily Lixiana (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Switzerland 71

Mar 06, 2015: NICE draft guidance recommends apixaban (Eliquis) for treating and preventing potentially fatal blood clots 72

Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO 73

Dec 08, 2014: Daiichi Sankyo Launches New Formulation of LIXIANA 60 mg Tablets (edoxaban) in Japan 74

Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 75

Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting 76

Oct 28, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo's Once-Daily SAVAYSA for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation 76

Sep 26, 2014: Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA (edoxaban) in Japan 77

Aug 30, 2014: Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE) 77

Jun 23, 2014: Regado Biosciences REG2 Demonstrates Dose and Concentration Dependent Suppression of Thrombin Generation 78

Appendix 79

Methodology 79

Coverage 79

Secondary Research 79

Primary Research 79

Expert Panel Validation 79

Contact Us 79

Disclaimer 80

List of Tables

Number of Products under Development for Venous Thromboembolism, H1 2015 8

Number of Products under Development for Venous Thromboembolism-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Venous Thromboembolism-Pipeline by Bayer AG, H1 2015 15

Venous Thromboembolism-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 16

Venous Thromboembolism-Pipeline by Gamma Therapeutics, Inc., H1 2015 17

Venous Thromboembolism-Pipeline by GlycoMimetics, Inc., H1 2015 18

Venous Thromboembolism-Pipeline by Green Cross Corporation, H1 2015 19

Venous Thromboembolism-Pipeline by Isis Pharmaceuticals, Inc., H1 2015 20

Venous Thromboembolism-Pipeline by Portola Pharmaceuticals, Inc., H1 2015 21

Venous Thromboembolism-Pipeline by Regado Biosciences, Inc., H1 2015 22

Venous Thromboembolism-Pipeline by Sanofi, H1 2015 23

Assessment by Monotherapy Products, H1 2015 24

Number of Products by Stage and Target, H1 2015 26

Number of Products by Stage and Mechanism of Action, H1 2015 28

Number of Products by Stage and Route of Administration, H1 2015 30

Number of Products by Stage and Molecule Type, H1 2015 32

Venous Thromboembolism Therapeutics-Recent Pipeline Updates, H1 2015 50

Venous Thromboembolism-Dormant Projects, H1 2015 69

Venous Thromboembolism-Discontinued Products, H1 2015 70

List of Figures

Number of Products under Development for Venous Thromboembolism, H1 2015 8

Number of Products under Development for Venous Thromboembolism-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Assessment by Monotherapy Products, H1 2015 24

Number of Products by Top 10 Targets, H1 2015 25

Number of Products by Stage and Top 10 Targets, H1 2015 26

Number of Products by Top 10 Mechanism of Actions, H1 2015 27

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28

Number of Products by Top 10 Routes of Administration, H1 2015 29

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30

Number of Products by Top 10 Molecule Types, H1 2015 31

Number of Products by Stage and Top 10 Molecule Types, H1 2015 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Bayer AG

Daiichi Sankyo Company, Limited

Gamma Therapeutics, Inc.

GlycoMimetics, Inc.

Green Cross Corporation

Isis Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc.

Regado Biosciences, Inc.

Sanofi

Venous Thromboembolism Therapeutic Products under Development, Key Players in Venous Thromboembolism Therapeutics, Venous Thromboembolism Pipeline Overview, Venous Thromboembolism Pipeline, Venous Thromboembolism Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com